SKCD in Early Relapsed/Refractory Multiple Myeloma

November 6, 2026 updated by: wen gao, Beijing Chao Yang Hospital

A Prospective, Multicenter, Open-Label, Single-Arm Phase II Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Carfilzomib, Aponermin, and Dexamethasone in Patients With Early Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a malignant hematologic neoplasm arising from abnormal plasma cells within the bone marrow. Although substantial therapeutic progress has been achieved over the past twenty years, MM remains an incurable disease for the vast majority of patients. When the disease relapses or becomes refractory after 1 to 3 prior lines of therapy (termed early relapsed or refractory multiple myeloma [RRMM]), achieving deep and durable remission during early salvage therapy is critical to extending long-term survival.

Current guideline-recommended second-line therapies exhibit distinct clinical challenges: standard triplet regimens lack head-to-head comparisons, novel cellular therapies (such as CAR-T) are costly and difficult to access, and optimal combinations for early relapse remain undefined. Furthermore, novel targeted therapeutics have predominantly originated overseas, highlighting an urgent need for effective regimens based on innovative domestic agents.

Therapeutic Rationale of the SKCD Regimen: This study evaluates a novel quadruplet combination regimen termed SKCD, comprising four complementary therapeutics:

  • 1. Sonrotoclax: Sonrotoclax (BGB-11417): A highly potent and selective oral BCL-2 inhibitor that restores the cell's internal (mitochondrial) apoptosis pathway.
  • 2. Carfilzomib: Carfilzomib: A second-generation selective proteasome inhibitor that inhibits myeloma cell proliferation and downregulates anti-apoptotic proteins like MCL-1.
  • 3. Aponermin (CPT): Aponermin (CPT): A first-in-class recombinant circularly permuted human TRAIL and DR4/DR5 agonist, independently developed in China and approved for RRMM, which selectively activates external (death receptor) apoptosis.
  • 4. Dexamethasone: Dexamethasone: A synthetic corticosteroid with established anti-myeloma activity that synergizes with BCL-2 and proteasome inhibitors.

Preclinical studies demonstrate that simultaneously stimulating internal mitochondrial apoptosis and external death receptor apoptosis produces synergistic anti-myeloma cytotoxicity. The primary objective of this Phase II study is to evaluate the clinical efficacy (assessed by the best complete response or better rate [>= CR]) and the safety profile of the SKCD quadruplet regimen followed by carfilzomib and dexamethasone (Kd) maintenance therapy in early relapsed RRMM.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Sonrotoclax is being investigated in combination with carfilzomib, aponermin, and dexamethasone for the treatment of early-line relapsed or refractory multiple myeloma. This use is outside the approved indications in China and is investigational.

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100020
        • Recruiting
        • Beijing Chao-Yang Hospital,Capital Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

Candidates must satisfy all of the following inclusion criteria to be enrolled in the study:

  • 1. Age: Age > 18 years, male or female.

  • 2. Measurable Disease: Diagnosed with multiple myeloma according to the 2014 IMWG diagnostic criteria, with measurable disease at screening defined by at least one of the following:

    1. Serum M-protein level > 10 g/L (1.0 g/dL); OR
    2. 24-hour urine M-protein excretion > 200 mg/24 hours; OR
    3. In light chain multiple myeloma without measurable serum or urine M-protein: serum involved free light chain (FLC) > 100 mg/L (10 mg/dL) with an abnormal serum FLC kappa/lambda ratio (normal reference range: 0.26-1.65).
  • 3. Disease Status & Life Expectancy: Patients with early relapsed or refractory multiple myeloma, with an anticipated life expectancy of >= 6 months.

  • 4. Prior Therapy Lines: Must have received 1 to 3 prior systemic treatment lines. Induction therapy followed by autologous stem cell transplantation (ASCT) with or without maintenance therapy is counted as a single line of therapy. Participants must have received at least one regimen containing a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib) and/or an immunomodulatory drug (e.g., lenalidomide, pomalidomide; excluding thalidomide monotherapy), and demonstrated disease progression or relapse during or after such therapy (single-agent or combination). Prior anti-CD38 monoclonal antibody exposure is permitted but not mandatory. Radiotherapy, bisphosphonate therapy, or a single brief course of corticosteroids (equivalent dose not exceeding dexamethasone 20 mg/day for <= 4 days) are not counted as prior systemic treatment lines.

  • 5. Documented Disease Progression: Documented evidence of progressive disease (PD) during or following the most recent anti-myeloma regimen based on IMWG consensus criteria. Progressive disease requires at least one of the following compared with the nadir value:

  • An increase of >= 25% in serum M-protein (with an absolute increase of >= 5 g/L); or an absolute increase of >= 10 g/L if baseline serum M-protein was >= 50 g/L;

  • An increase of >= 25% in 24-hour urine M-protein (with an absolute increase of >= 200 mg/24 h);

  • In patients without measurable serum and urine M-protein, an increase of >= 25% in the difference between involved and uninvolved FLC levels (dFLC, with an absolute increase > 100 mg/L);

  • In patients without measurable serum/urine M-protein and involved FLC, an increase of >= 25% in bone marrow plasma cell percentage (with an absolute increase of >= 10%);

  • Development of new extramedullary plasmacytomas: an increase of >= 50% in the sum of the products of the perpendicular diameters (SPD) of > 1 existing measurable lesion compared to nadir, or an increase of >= 50% in the longest diameter of a pre-existing lesion >= 1 cm;

  • When circulating plasma cells represent the only measurable parameter, an increase of > 50% in circulating plasma cells (with an absolute count of at least 200 cells/uL).

  • 6. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 at screening and prior to initiation of study treatment.

  • 7. Organ and Laboratory Function: Adequate hematologic, hepatic, renal, and metabolic organ function prior to enrollment, satisfying:

  • Hemoglobin >= 80 g/L (without red blood cell transfusions or erythropoietin within 7 days prior to laboratory assessment);

  • Platelet count: > 75 x 10⁹/L in patients with < 50% bone marrow nucleated cells composed of plasma cells; > 50 x 10⁹/L in patients with >= 50% bone marrow plasma cells (without platelet transfusions or thrombopoietin receptor agonists within 7 days prior to assessment);

  • Absolute Neutrophil Count (ANC) > 0.5 x 10⁹/L (growth factor support permitted, but G-CSF or GM-CSF must be discontinued for >= 7 days, and pegylated G-CSF for >= 14 days prior to assessment);

  • Hepatic function: AST and ALT <= 2.5 x ULN; Total bilirubin <= 2.5 x ULN, except in patients with congenital hyperbilirubinemia such as Gilbert syndrome (in which direct bilirubin must be < 1.5 x ULN);

  • Renal function: Estimated glomerular filtration rate (eGFR) > 30 mL/min, calculated using the Modification of Diet in Renal Disease (MDRD) equation or measured by 24-hour urinary creatinine clearance;

  • Serum calcium: Albumin-corrected serum calcium <= 14 mg/dL (< 3.5 mmol/L) or ionized calcium <= 6.5 mg/dL.

  • 8. Disease Subtype Definitions: Relapsed, refractory, or clinical relapse defined as follows:

  • Relapsed Disease: Patients who initially achieved a response to prior therapy and subsequently developed confirmed disease progression per IMWG criteria > 60 days after therapy cessation.

  • Refractory Disease: Patients who experienced disease progression per IMWG criteria during prior therapy or within < 60 days of discontinuing prior therapy, or had an M-protein increase of >= 25%.

  • Clinical Relapse: Defined by >= 1 of the following: (1) Development of new bone lesions or soft-tissue plasmacytomas (excluding osteoporotic fractures); (2) Definite increase in the size of existing plasmacytomas or bone lesions (>= 50% increase in SPD of measurable lesions and absolute increase >= 1 cm); (3) Hypercalcemia (> 2.75 mmol/L); (4) Decrease in hemoglobin concentration >= 20 g/L (unrelated to therapy or non-MM causes); (5) Increase in serum creatinine >= 176.8 umol/L (2 mg/dL) from initiation of MM therapy, attributable to myeloma; (6) Hyperviscosity related to serum M-protein.

  • 9. Informed Consent: Voluntary written informed consent signed by the patient or legally authorized representative.

Exclusion Criteria

Candidates meeting any of the following exclusion criteria shall be excluded from study participation:

  • 1. Hypersensitivity: Known contraindication, life-threatening allergy, severe hypersensitivity, or intolerance to any study drug active ingredients or excipients.
  • 2. Prior Antineoplastic Therapy Washout: Prior therapy washout requirements:
  • Targeted therapy, epigenetic therapy, or investigational drug treatment within 21 days or > 5 elimination half-lives (whichever is shorter) prior to first study dose; or use of an invasive investigational medical device;
  • Administration of an approved or emergency-use investigational vaccine (other than SARS-CoV-2 vaccines) within 4 weeks; administration of live attenuated vaccines within 4 weeks;
  • Monoclonal antibody therapy within 21 days;
  • Cytotoxic chemotherapy within 21 days;
  • Proteasome inhibitor (PI) therapy within 14 days;
  • Immunomodulatory drug (IMiD) therapy within 14 days;
  • Radiotherapy within 14 days, or focal palliative radiotherapy within 7 days.
  • 3. CNS Involvement: Known active central nervous system (CNS) involvement or clinical signs of meningeal myeloma. In suspected cases, brain MRI and lumbar puncture cytology must be negative.
  • 4. Specific Hematologic Conditions: Diagnosis of plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes), or primary light chain (AL) amyloidosis at screening.
  • 5. Second Malignancies: Non-hematologic malignancy diagnosed within 3 years prior to enrollment (unless curatively treated), or presence of therapy-related myelodysplastic syndrome (t-MDS).
  • 6. Cardiovascular Diseases: Cardiovascular diseases including:
  • New York Heart Association (NYHA) Class III or IV congestive heart failure;
  • Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment;
  • Clinically significant ventricular arrhythmias, or history of unexplained syncope;
  • History of severe non-ischemic cardiomyopathy.
  • 7. Infectious & Pulmonary Diseases: Infectious, pulmonary, or neurologic conditions including:
  • Uncontrolled hepatitis B virus infection (positive HBsAg or HBV-DNA): if infection status is indeterminate, HBV-DNA viral quantification must be performed. Active hepatitis C virus (HCV) infection, defined as positive HCV-RNA. Patients with a history of HCV antibody positivity must undergo HCV-RNA testing; patients with resolved chronic hepatitis C who completed antiviral therapy and maintained undetectable HCV-RNA for >= 12 weeks post-treatment are eligible;
  • Chronic obstructive pulmonary disease (COPD) with FEV1 < 50% of predicted normal value;
  • Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any type;
  • Significant peripheral neuropathy at baseline (Grade 3, Grade 4, or Grade 2 with associated pain).
  • 8. Major Surgery: Major surgery within 2 weeks prior to initiating study treatment, incomplete surgical recovery, or major elective surgery planned during the study treatment period or within 2 weeks following the last study dose.
  • 9. Investigator Discretion: Any medical, psychiatric, or other condition that, in the opinion of the investigator, makes the patient unsuitable for trial participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SKCD:Sonrotoclax+Carfilzomib+Aponermin+Dexamethasone

Eligible patients will receive the SKCD regimen for up to 9 cycles (28 days per cycle). Patients who do not develop disease progression or meet withdrawal criteria proceed to Kd maintenance therapy:

  • Cycle 1 (C1, 28-day cycle): Sonrotoclax: Oral dose ramp-up / escalated to 320 mg QD, PO, Days 1-28; Carfilzomib: 20 mg/m² IV on Days 1 and 2, then 27 mg/m² IV on Days 8, 9, 15, and 16; Aponermin (CPT): 10 mg/kg IV on Days 1-5; Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22, and 23.
  • Cycles 2 to 9 (C2-C9, 28-day cycles): Sonrotoclax: 320 mg QD, PO, Days 1-28; Carfilzomib: 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16; Aponermin (CPT): 10 mg/kg IV on Days 1-5; Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22, and 23.
  • Post-Cycle 9 Kd Maintenance Phase (28-day cycles): Carfilzomib: 27 mg/m² IV on Days 1, 2, 15, and 16; Dexamethasone: 10 mg PO or IV on Days 1, 2, 15, and 16.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Best Complete Response or Better Rate (≥CR)
Time Frame: From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a confirmed complete response (CR) or stringent complete response (sCR), according to the International Myeloma Working Group criteria, during the first nine cycles of SKCD treatment and before initiation of Kd maintenance therapy.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Best Complete Response or Better Rate During SKCD and Kd Maintenance
Time Frame: From enrollment to the end of treatment at 9 cycles (28 days per cycle)].

The proportion of participants whose best confirmed response is complete response (CR) or stringent complete response (sCR), assessed according to the International Myeloma Working Group criteria from the first dose of study treatment through SKCD treatment and subsequent Kd maintenance, before disease progression or initiation of a new anti-myeloma treatment, whichever occurs first.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)].
Overall Response Rate (ORR)
Time Frame: From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a partial response (PR) or better as their best response, assessed according to the International Myeloma Working Group (IMWG) response criteria.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)
Very Good Partial Response or Better Rate (≥VGPR)
Time Frame: From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) as their best response, assessed according to the International Myeloma Working Group (IMWG) response criteria.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)
Minimal Residual Disease (MRD) Negativity Rate by Next-Generation Flow Cytometry
Time Frame: From enrollment to the end of treatment at 9 cycles (28 days per cycle), during maintenance treatment

The proportion of participants who achieve minimal residual disease (MRD) negativity in bone marrow, assessed by next-generation flow cytometry (NGF) at a sensitivity of 10^-5. Bone marrow MRD is assessed when a participant achieves a very good partial response (VGPR) or better. The proportion of participants who achieve MRD negativity among participants who undergo bone marrow MRD testing by next-generation flow cytometry at a sensitivity of 10^-5.

From enrollment to the end of treatment at 9 cycles (28 days per cycle), during maintenance treatment
Progression-Free Survival (PFS)
Time Frame: From the first dose of study treatment until disease progression or death from any cause, assessed up to 36 months.

The time from the first dose of study treatment to the first documented disease progression, assessed according to the International Myeloma Working Group (IMWG) response criteria, or death from any cause, whichever occurs first.

From the first dose of study treatment until disease progression or death from any cause, assessed up to 36 months.
Overall Survival (OS)
Time Frame: From the first dose of study treatment until death for any cause, assessed up to 36 months.

The time from the first dose of study treatment to death from any cause.

From the first dose of study treatment until death for any cause, assessed up to 36 months.
Incidence and Severity of Adverse Events
Time Frame: From signing of informed consent through the post-treatment safety visit 60 days after the final dose of study treatment.

Number and proportion of participants experiencing adverse events, serious adverse events, and adverse events leading to dose modification or treatment discontinuation. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0.

From signing of informed consent through the post-treatment safety visit 60 days after the final dose of study treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Wen Gao, MD, Beijing Chao Yang Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 31, 2026

Primary Completion (Estimated)

March 31, 2030

Study Completion (Estimated)

March 31, 2030

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 6, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • LGH-2026-LI-104

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be made publicly available due to participant privacy and confidentiality considerations. Aggregate study results may be reported in scientific publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.